CO5690570A2 - Nueva combinacion sinergistica que comprende roflumilast y formoterol - Google Patents

Nueva combinacion sinergistica que comprende roflumilast y formoterol

Info

Publication number
CO5690570A2
CO5690570A2 CO05062787A CO05062787A CO5690570A2 CO 5690570 A2 CO5690570 A2 CO 5690570A2 CO 05062787 A CO05062787 A CO 05062787A CO 05062787 A CO05062787 A CO 05062787A CO 5690570 A2 CO5690570 A2 CO 5690570A2
Authority
CO
Colombia
Prior art keywords
formoterol
roflumilast
daily dose
combined use
combination including
Prior art date
Application number
CO05062787A
Other languages
English (en)
Spanish (es)
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Christian Weimar
Degenhard Marx
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CO5690570A2 publication Critical patent/CO5690570A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CO05062787A 2002-11-27 2005-06-27 Nueva combinacion sinergistica que comprende roflumilast y formoterol CO5690570A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27

Publications (1)

Publication Number Publication Date
CO5690570A2 true CO5690570A2 (es) 2006-10-31

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062787A CO5690570A2 (es) 2002-11-27 2005-06-27 Nueva combinacion sinergistica que comprende roflumilast y formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (cg-RX-API-DMAC7.html)
EP (1) EP1567139B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006508994A (cg-RX-API-DMAC7.html)
KR (1) KR101071798B1 (cg-RX-API-DMAC7.html)
CN (1) CN100346777C (cg-RX-API-DMAC7.html)
AT (1) ATE399543T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003292120B2 (cg-RX-API-DMAC7.html)
BR (1) BR0316451A (cg-RX-API-DMAC7.html)
CA (1) CA2506962C (cg-RX-API-DMAC7.html)
CO (1) CO5690570A2 (cg-RX-API-DMAC7.html)
CY (1) CY1110369T1 (cg-RX-API-DMAC7.html)
DE (1) DE60321953D1 (cg-RX-API-DMAC7.html)
DK (1) DK1567139T3 (cg-RX-API-DMAC7.html)
EA (1) EA009935B1 (cg-RX-API-DMAC7.html)
ES (1) ES2309357T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20050579B1 (cg-RX-API-DMAC7.html)
IL (1) IL168308A (cg-RX-API-DMAC7.html)
IS (1) IS2575B (cg-RX-API-DMAC7.html)
MA (1) MA27539A1 (cg-RX-API-DMAC7.html)
ME (1) ME00489B (cg-RX-API-DMAC7.html)
MX (1) MXPA05005437A (cg-RX-API-DMAC7.html)
NO (1) NO334247B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ540659A (cg-RX-API-DMAC7.html)
PL (1) PL216752B1 (cg-RX-API-DMAC7.html)
PT (1) PT1567139E (cg-RX-API-DMAC7.html)
RS (1) RS51081B (cg-RX-API-DMAC7.html)
SI (1) SI1567139T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN05131A1 (cg-RX-API-DMAC7.html)
UA (1) UA83018C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004047829A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200503308B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
UA98466C2 (uk) * 2006-07-05 2012-05-25 Нікомед Гмбх КОМБІНАЦІЯ ІНГІБІТОРА HMG-CоA-РЕДУКТАЗИ Й ІНГІБІТОРА ФОСФОДІЕСТЕРАЗИ 4, ПРИЗНАЧЕНА ДЛЯ ЛІКУВАННЯ ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ ЛЕГЕНІВ
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
EA033113B1 (ru) * 2013-01-28 2019-08-30 Инкозен Терапьютикс Пвт. Лтд. Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EA001758B1 (ru) * 1997-02-17 2001-08-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Композиции для лечения респираторного дистресс-синдрома взрослых или респираторного дистресс-синдрома новорожденных, содержащие 3-(циклопропилметокси)-n-(3,5-дихлор-4-пиридинил)-4-(дифторметокси)бензамид и легочное поверхностно-активное вещество
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
EP1671651B1 (en) * 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2314052T3 (es) * 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.

Also Published As

Publication number Publication date
NO334247B1 (no) 2014-01-20
KR101071798B1 (ko) 2011-10-11
HRP20050579A2 (hr) 2006-04-30
WO2004047829A1 (en) 2004-06-10
NZ540659A (en) 2007-05-31
CA2506962A1 (en) 2004-06-10
CN1713903A (zh) 2005-12-28
MA27539A1 (fr) 2005-09-01
PL377732A1 (pl) 2006-02-06
RS20050382A (sr) 2007-08-03
EP1567139A1 (en) 2005-08-31
EP1567139B1 (en) 2008-07-02
CA2506962C (en) 2012-01-03
KR20050085104A (ko) 2005-08-29
AU2003292120A1 (en) 2004-06-18
SI1567139T1 (sl) 2008-12-31
MXPA05005437A (es) 2005-08-03
PT1567139E (pt) 2008-10-01
JP2006508994A (ja) 2006-03-16
IS7898A (is) 2005-06-20
HK1081861A1 (en) 2006-05-26
BR0316451A (pt) 2005-10-11
HRP20050579B1 (hr) 2014-01-31
CN100346777C (zh) 2007-11-07
ES2309357T3 (es) 2008-12-16
UA83018C2 (uk) 2008-06-10
DE60321953D1 (de) 2008-08-14
TNSN05131A1 (en) 2007-05-14
ATE399543T1 (de) 2008-07-15
NO20052999L (no) 2005-06-17
EA200500774A1 (ru) 2005-12-29
RS51081B (sr) 2010-10-31
IS2575B (is) 2010-02-15
IL168308A (en) 2010-12-30
WO2004047829A8 (en) 2005-06-30
CY1110369T1 (el) 2015-04-29
US20060142308A1 (en) 2006-06-29
AU2003292120B2 (en) 2010-01-21
ME00489B (me) 2011-10-10
EA009935B1 (ru) 2008-04-28
PL216752B1 (pl) 2014-05-30
ZA200503308B (en) 2006-11-29
DK1567139T3 (da) 2008-11-03

Similar Documents

Publication Publication Date Title
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
ES2202265T3 (es) Aerosol medicamentoso en el tratamiento o la prevencion del dolor.
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
ES2123576T3 (es) Medicamentos.
ES2162927T3 (es) Formulacion para la aplicacion por inhalacion.
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR101593A2 (es) Formulación superfina de formoterol
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
CO5611092A2 (es) Formulacion superfina de formoterol
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
BR112017026417B1 (pt) Formulação para o tratamento de distúrbios da boca, garganta e vias respiratórias
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CO5540290A2 (es) Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias
GB2430623A (en) Medicaments for treating chronic respiratory disease
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
JPH09500610A (ja) 経鼻芳香放出組成物
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
BRPI0518741A2 (pt) uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
Ko et al. Effects of topical O24 essential oils on patients with fibromyalgia syndrome: a randomized, placebo controlled pilot study
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso

Legal Events

Date Code Title Description
FA Application withdrawn